StockNews.AI
RLMD
StockNews.AI
146 days

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

1. Relmada Therapeutics will host a conference call on March 27, 2025. 2. Discussion will cover recent business progress and Q4 financial results. 3. Their lead program, NDV-01, focuses on bladder cancer in Phase 2 study. 4. Sepranolone is preparing for further studies for compulsion-related disorders. 5. The webcast replay will be accessible on the Relmada website.

Earnings
-6.99%Current Return
VS
-1.32%S&P 500
$0.320403/26 09:07 AM EDTEvent Start
$0.29803/27 03:54 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

The upcoming conference and potential breakthroughs in clinical programs can attract investor interest, similar to other biotech firms that saw price increases following positive earnings reports or news of progress in clinical trials.

How important is it?

The conference will shed light on financial performance and clinical pipeline, crucial for investor confidence.

Why Short Term?

The conference is imminent, likely leading to immediate market reactions based on revealed information.

Related Companies

BXRXPTNYAVDL
March 26, 2025 09:00 ET  | Source: Relmada Therapeutics CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Information: Date: Thursday, March 27, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13751458Webcast Access: Click Here A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar. About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations. Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase 2b-ready investigational program for compulsion-related disorders including Tourette’s Syndrome into further studies. For more information, visit www.relmada.com. Investor Contact:Brian RitchieLifeSci Advisorsbritchie@lifesciadvisors.com Media Inquiries:Corporate Communicationsmedia@relmada.com

Related News